Fig. 3
From: Increased TSPO alleviates neuropathic pain by preventing pyroptosis via the AMPK-PGC-1α pathway
Pharmacological increase but not decrease of TSPO alleviated neuropathic pain. A Schematic diagram of the experimental flow. B Behavioral changes following TSPO inhibition by PK 11195 were assessed using von Frey testing at multiple time points (days 0, 3, 7, 14, and 21), n = 10 per group. C Representative immunofluorescence images showing c-Fos and NeuN co-staining after PK 11195 treatment, Scale bar = 50 μm. D, E ELISA results showing the levels of IL-1β and IL-18 after PK 11195 administration, n = 6 per group. F Western blot showing the expression levels of TSPO, NLRP3, Caspase-1 and GSDMD-N after PK 11195 treatment. G Behavioral tests of mice receiving different concentrations of Ro 5–4864, n = 6 per group. H Behavioral changes following TSPO activation by Ro 5–4864 were assessed using von Frey testing at multiple time points (days 0, 3, 7, 14, and 21), n = 10 per group. I Western blot showing the expression levels of TSPO, NLRP3, Caspase-1 and GSDMD-N after Ro 5–4864 treatment. J Representative immunofluorescence images showing c-Fos and NeuN co-staining after Ro 5–4864 treatment, Scale bar = 50 μm. K ELISA results showing the levels of the IL-1β and IL-18 after Ro 5–4864 treatment, n = 6 per group. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001